For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230824:nRSX2698Ka&default-theme=true
RNS Number : 2698K Benchmark Holdings PLC 24 August 2023
24 August 2023
Information within this announcement is deemed by the Company to constitute
inside information under the Market Abuse Regulations (EU) No. 596/2014
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Q3 & Year to Date Results
(Three months and nine months ended 30 June 2023)
Strong performance YTD Q3
Q3 reflects anticipated seasonality in Health and conditions in the global
shrimp market
In compliance with the terms of the Company's unsecured Green bond, which
requires it to publish quarterly financial information, Benchmark, the
aquaculture biotechnology business, announces its unaudited results for the
three months ended 30 June 2023 (the "Period"), which constitutes the third
quarter for the fiscal year ("FY") 2023, and its year to date unaudited
results for the nine months ended 30 June 2023. All Q3 FY23, Q3 FY22, Q3 YTD
FY23 and Q3 YTD FY22 figures quoted in this announcement are based on
unaudited accounts.
Financial highlights
Q3 FY23
· Q3 FY23 revenues 6% below the prior year (-1% CER) with growth in
Genetics offset by lower revenues in Advanced Nutrition due to ongoing
softness in shrimp markets. Health revenues broadly in line with the prior
year.
· Q3 FY23 Adjusted EBITDA excluding fair value movements from
biological assets 29% below the prior year (-19% CER) as a result of lower
revenues, adverse forex and quarter specific factors including an increase in
third party production costs for our salmon harvest income, partially offset
by ongoing cost control.
· Adjusted Operating Loss excluding FV movement in biological assets of
£1.7m (Q3 FY22: £0.7m loss).
· Loss before tax reduced substantially £4.7m (Q3 FY22: £11.2m loss)
due to a material reduction in net finance costs as a result of forex
movements and mark to market movements in the value of financial derivatives.
Q3 YTD FY23 - Significant year on year growth and improved profitability
· Q3 YTD FY23 revenues 15% ahead of the prior year (+13% CER), driven
by growth in Genetics and Health; Advanced Nutrition revenues in line with
prior year.
· Adjusted EBITDA excluding fair value movements from biological assets
27% ahead of the prior year (+27% CER) driven primarily by growth in Health
and resilience in Advanced Nutrition. Adjusted EBITDA margin (excluding fair
value movements from biological assets) of 19% (Q3 YTD FY22: 17%).
· Adjusted Operating Profit excluding FV movement in biological assets
more than triple to £9.7m (Q3 YTD FY22: £3.2m).
· Loss before tax significantly reduced to £6.6m (Q3 YTD FY22:
£16.4m).
· Operating cash significantly improved to £11.2m inflow versus prior
year (Q3 YTD FY22: cash outflow of £2.2m).
· Cash of £32.9m and liquidity of £45.1m (cash and available
facility) as at 30 June 2023.
· Net debt (excluding lease liabilities) continues to reduce year on
year to £45.7m as at 30 June 2023 (31 March 2023: £44.5m; 30 September 2022:
£47.5m).
Business Area Highlights
· Advanced Nutrition - commercial focus and cost control mitigate
impact of shrimp market conditions
o Q3 revenues 17% below the prior year (-18% CER) reflecting global shrimp
market. YTD Q3 23 revenues in line with prior year.
o Despite drop in revenue, Q3 Adjusted EBITDA 20% above Q3 2022 as a result
of product mix, lower freight costs, and ongoing efficiency programme. YTD Q3
Adjusted EBITDA 4% ahead of the prior year.
o Conditions in global shrimp markets affecting demand for our nutritional
solutions
· Genetics - revenue growth offset by quarter specific factors
o Q3 revenues 10% above Q3 2022 (+21% CER) driven by higher sales of salmon
eggs and harvest revenues
§ Growth in salmon egg sales: 68.5m eggs sold in Q3 FY23 (Q3 FY22: 59.4m
eggs)
o YTD Q3 revenues 23% (+28% CER) ahead of prior year
o Q3 Adjusted EBITDA excluding FV movement in biological assets 44% below
the prior year (-29% CER) due to a number of factors including:
§ higher third-party production costs related to harvest income
§ lower capitalisation of biological asset production costs, and
§ forex headwinds
o YTD Q3 Adjusted EBITDA excluding FV movements 5% below the prior year (CER
+7% higher).
· Health - results reflective of seasonality in sea lice treatments
o Q3 revenues broadly in line with Q3 2022 at 1% below (+5% CER)
o YTD Q3 revenues 57% ahead of prior year (+59% CER)
o Q3 Adjusted EBITDA loss of £1.0m (Q3 FY22 loss £0.6m) due to low
utilisation of CleanTreat® vessels during low season for sea lice treatments
o YTD Q3 Adjusted EBITDA of £5.6m (YTD Q3 2022: £0.5m loss).
o The Company is making progress in the development of the new configuration
and business model for CleanTreat® with partners MMC and SALT
· Group integration initiatives - steps taken to realise synergies and
strengthen commercial focus by combining Health and Genetics activities within
Salmon under common leadership with a combined commercial offering.
Current trading and outlook
· Trading within market expectations for FY23:
o Good visibility in Genetics for the remainder of the year
o Advanced Nutrition will continue to be influenced by weak global shrimp
market conditions
o Health expected to benefit from seasonal increase in sea lice treatments
during Q4
o Efforts continue to focus on profitability and cash generation driven by
commercial success and integration synergies
£m Q3 YTD FY23 Q3 YTD FY22 % CER Q3 FY22 % CER
Q3 YTD FY23 Q3 FY23 Q3 FY23
Revenue 133.1 115.5 +13% 34.3 36.3 -1%
+15% -6%
Adjusted
Adjusted EBITDA(1) 27.1 22.4 +21% 5.1 6.6 -13%
+21% -23%
Adj. EBITDA excluding biological asset fair value movements 25.4 20.0 +27% 3.6 5.1 -19%
+27% -29%
Adjusted Operating Profit/(Loss)(2) 11.4 5.6 107% (0.2) 0.8 -58%
104% -129%
Adj. Operating profit excluding biological asset fair value movements 9.7 3.2 206% (1.7) (0.7) -83%
207% -149%
Statutory
Operating loss (4.2) (6.1) 35% (4.5) (4.0) 1%
32% -13%
Loss before tax (6.6) (16.4) 64% (4.7) (11.2) 63%
60% 58%
Basic loss per share (p) (1.27) (3.24) (0.70) (1.90)
Net debt(3) (66.9) (89.1) (66.9) (89.1)
Net debt(3) excluding lease liabilities (45.7) (59.3) (45.7) (59.3)
Business Area summary
£m Q3 YTD FY23 Q3 YTD FY22 % CER Q3 FY22 % CER
Q3 YTD FY23 Q3 FY23 Q3 FY23
Revenue
Advanced Nutrition 61.4 61.4 -8% 16.1 19.4 -18%
0% -17%
Genetics 48.9 39.7 +28% 14.4 13.1 +21%
+23% +10%
Health 22.9 14.5 +59% 3.8 3.8 +5%
+57% -1%
Adjusted EBITDA(1)
Advanced Nutrition 14.9 14.3 -4% 3.4 2.8 +20%
+4% +20%
Genetics 9.3 10.5 0% 3.4 4.8 -18%
-11% -30%
- Net of fair value movements in biological assets 7.6 8.1 +7% 1.9 3.4 -29%
-5% -44%
Health 5.6 (0.5) 1,186% (1.0) (0.6) -57%
+1,188% -67%
*Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure
(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs
(3) Net debt is cash and cash equivalents less loans and borrowings
Trond Williksen, CEO, commented:
"Our Q3 trading reflects the anticipated low season for our Health solutions
in the salmon industry, as well as the continuing adverse market conditions in
the global shrimp market. Despite these headwinds we have delivered strong
year to date results, with double digit growth in revenues and earnings
compared to the prior year.
"For the remainder of the year we have good visibility in Genetics and are
moving into the main season for sea lice treatments in Health. Notwithstanding
the prevailing market conditions for Advanced Nutrition, we continue to
demonstrate momentum in our business and the resilience of our diversified
business model to face cyclical fluctuations in our end markets. We continue
our strong commercial focus to ensure the further growth and profitable
development of the Group."
Presentation for analysts and institutional investors at 08.00 UK time (09.00
CET)
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a presentation for analysts and institutional investors on
the day at 08.00 UK time.
The presentation will be held in person at DnB's offices in Oslo at Dronning
Eufemias gate 30, 0191 Oslo, Norway. If you would like to attend in person,
please contact Henriette Christensen at henriette.gjeldvik.christensen@dnb.no
(mailto:henriette.gjeldvik.christensen@dnb.no)
A live webcast of the presentation will be available for analysts and
investors to join remotely at the following link: Benchmark Holdings Webcast
Q3 2023 (royalcast.com)
(https://protect-eu.mimecast.com/s/uJUKCwmG9tLxKlGcV2iIv?domain=channel.royalcast.com)
A copy of the presentation can be found on the Company's website
https://www.benchmarkplc.com/investors/reports-presentations/
Equity Development webcast at 12.00 UK time
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a second webcast for retail investors and wealth managers on
the day at 12.00 UK time. The webcast is open to all existing and potential
shareholders.
To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-q3results-presentation-24aug2023
(https://www.equitydevelopment.co.uk/news-and-events/benchmark-q3results-presentation-24aug2023)
A recording of the presentation will be available after the event on the
Equity Development website
(https://www.equitydevelopment.co.uk/research/tag/benchmark-holdings) .
(https://www.equitydevelopment.co.uk/research/tag/benchmark-holdings)
Enquiries
For further information, please contact:
Benchmark Holdings plc benchmark@mphc.com
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD) Tel: 020 7260 1000
Freddie Barnfield, Duncan Monteith, Sher Shah
MHP Tel: +44(0) 20 3128 8004
Katie Hunt, Reg Hoare, Veronica
Farah
benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)
About Benchmark
Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth and animal health and welfare.
Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses many of the major aquaculture species -
salmon, shrimp, sea bass and sea bream, and tilapia - in all the major
aquaculture regions around the world. Find out more at www.benchmarkplc.com
Management Report
Q3 FY23 commentary
Benchmark reported revenues of £34.3m, 6% below the prior year revenue of
£36.3m. This resulted from revenue growth in Genetics of 10% being offset by
a 17% drop in Advanced Nutrition as a result of prevailing conditions in the
global shrimp markets during the period. Revenues in the Health business
area broadly in line with the prior year (-1%). On a constant exchange rate
(CER) basis Group revenues were 1% below the prior year, a reflection of some
forex headwinds in the quarter.
Adjusted EBITDA (excluding fair value uplift from biological assets) was
£3.6m, 29% (CER -19%) below the prior year (Q3 FY22: £5.1m). This was
mainly due to a reduction in Adjusted EBITDA in Genetics and Health. Despite
lower revenues in Advanced Nutrition, Adjusted EBITDA showed growth of 20% in
Q3 FY23 due to continued commercial focus and cost control. Further detail
on business area performance is provided below.
Operating costs for the Group of £10.6m were 7% below last year (Q3 FY22:
£11.5m) with a decrease in all business areas demonstrating the focus on
continued cost control. R&D expenses of £1.5m were broadly in line with
the prior year (Q3 FY22: £1.4m). Depreciation and amortisation decreased to
£9.0m (Q3 FY22: £10.1m), taking Group operating loss for the quarter to
£4.5m (Q3 FY22: £4.0m). The Adjusted Operating loss excluding fair value
movements in biological assets was £1.7m (Q3 FY22: £0.7m).
Net finance costs were £0.2m, significantly below the comparative period (Q3
FY22: £7.3m), due to a combination of the portion of the movement in the fair
value of the derivative instrument which is ineffective for hedge accounting
purposes and forex movements. The ineffective portion of the movement in the
fair value of the derivative in the period was a gain of £1.1m (Q3 YTD FY22:
£2.3m loss) and the Group had net forex gains of £1.3m (Q3 FY22:
£3.1m). As a result of these year-on-year movements, the loss before tax in
the quarter was £4.7m (Q3 FY22: £11.2m). Interest charges, including
interest on right of use assets increased £0.9m primarily following increased
interest rates from the refinancing in FY22.
The tax charge in the period was a £76,000 credit (Q3 FY22: £1.6m charge)
due to lower profits in Advanced Nutrition and Genetics in the quarter in
territories where no loss relief was available. The resulting loss after tax
for the quarter was £4.6m (Q3 FY22: loss £12.8m).
We continue our efforts to enhance our commercial focus and integrate the
Group to drive synergies. In the period we brought together our Health and
Genetics operations under common leadership which drives the synergies from
our salmon product portfolio across the two business areas and results in an
integrated customer-centric offering.
Advanced Nutrition
Advanced Nutrition revenues were down 17% (CER -18%) compared to Q3 2022, a
direct result of conditions in the global shrimp markets which remained
unfavourable throughout the year. In 2023 the global shrimp markets have
been affected by a number of factors including inflation in the US and in
Europe which have reduced consumption, creating oversupply and driving down
farm gate prices for shrimp. Imports to the US and Europe are estimated to be
20%-30% below the prior year. At the same time shrimp producers have been
faced with increased costs particularly in aquafeed and have reacted by
reducing pond stocking thus limiting demand for our products. This
environment is expected to continue for the remainder of the year. By product
area, sales of Artemia were -21%, Diets -16% and Health -8% against Q3 2022.
Against this backdrop our business has demonstrated resilience, making
commercial decisions to maintain and strengthen our market position, while
taking action to align our resources and cost base to the market environment.
As a result of this, and with a shift in the product mix, our Advanced
Nutrition business delivered an increase in Adjusted EBITDA of 20% to £3.4m
(Q3 FY22: £2.8m) (CER 20%).
Revenue YTD at £61.4m was in line with the prior year (Q3 YTD FY22: £61.4m)
with assistance from forex movements (CER -8% below prior year); Adjusted
EBITDA was 4% above (CER -4% below) prior year at £14.9m (Q3 YTD FY22:
£14.3m) due to continued commercial focus and cost control.
Genetics
Despite forex headwinds with weak NOK and ISK, Genetics delivered good revenue
growth in Q3 FY23 with revenues of £14.4m, 10% above the prior year (Q3 FY22:
£13.1m) (+21% CER). This was driven mainly by strong salmon egg sales,
together with improved revenue from harvest income and smolt sales, partially
offset by a reduction in sales of SPR shrimp and lumpfish. Sales of salmon
eggs were 39% higher than the prior year while sales from shrimp were below
the prior year at £0.2m (Q3 FY22: £0.4m) and revenues from tilapia were
flat.
Our work to refine the shrimp genetics product line is ongoing and we have
lowered our commercial activities during this period. Prevailing conditions in
the shrimp markets have also affected this area of our business. As
previously announced, we are conducting a strategic review of our tilapia
operations and are well advanced. This has had a bearing on our commercial
activities in this area in the short run.
Adjusted EBITDA for Q3 FY23 excluding fair value movements of biological
assets was down 44% to £1.9m (Q3 FY22: £3.4m) due to a number of factors
specific to Q3. These included forex pressure from weak NOK and ISK (-£0.6m),
a £1.2m reduction in the margin from harvest income where third party
production costs have been significantly higher than the prior year, together
with our own cost inflation, and lower capitalisation of production costs as a
result of lower closing stock levels (-£1.2m). Biological assets were higher
in Q3 FY22 in anticipation of higher sales in Q4 FY22 due to supply issues in
the market a year ago. On a constant currency basis Adjusted EBITDA
excluding FV movements was down -29% compared to Q3 FY22.
Revenue YTD at £48.9m was 23% higher than the prior year (Q3 YTD FY22:
£39.7m) and Adjusted EBITDA excluding fair value movements in biological
assets was 5% below the prior year at £7.6m (Q3 YTD FY22: £8.1m) (+7% CER).
Health
Revenues in Q3 FY23 were £3.8m, in line with the prior year (Q3 FY22:
£3.8m). Sales from Ectosan® Vet and CleanTreat® were £2.7m, 25% ahead of
the prior year, while Salmosan® sales for the quarter were below prior year
at £1.1m (Q3 FY22 £1.6m) following strong sales in Q2. Adjusted EBITDA was
a loss of £1.0m (Q3 FY22: loss of £0.6m) as a result of the low utilisation
rate of the CleanTreat® assets in the quarter due to it being the low season
for sea lice treatments. £0.9m of the revenue in the period (Q3 FY22:
£0.2m) was derived from recharging vessel and fuel costs associated with the
Ectosan® Vet and CleanTreat® operations. YTD revenue was significantly
ahead of the prior year at £22.9m (Q3 YTD FY22: £14.5m) with corresponding
YTD Adjusted EBITDA also higher at £5.6m (YTD Q3 FY22 £0.5m loss).
Q3 has seasonally been a slow period for sea lice treatments as anticipated,
however going into Q4, we expect increased activity. We continue to progress
the development of a new configuration of the Group's CleanTreat® systems
with our partners MMC, a wellboat equipment provider and SALT, a ship
designer. The new configuration is based on the next generation of large
wellboats, which form a core part of our customers' infrastructure and is of
strategic importance for the ongoing commercial roll-out of Ectosan® Vet and
CleanTreat®.
Q3 YTD FY23 Commentary
Q3 YTD the Group delivered 15% growth (CER +13%) in revenue at £133.1m and
27% growth (CER +27%) in Adjusted EBITDA excluding fair value movements from
biological assets at £25.4m. Genetics and Health reported strong revenue
growth of 23% and 57% respectively while revenues in Advanced Nutrition were
in line with the prior year despite significant headwinds in the shrimp
markets.
Operating costs were £34.7m, an 11% increase from the prior year (Q3 YTD
FY22: £31.4) due to higher activity levels, cost inflation and the impact of
forex movements, while R&D expenses of £4.5m were 4% lower than the
comparative period in the previous year (Q3 YTD FY22: £4.7m). Total R&D
investment including capitalised development costs was £4.9m, £1.4m below
the prior year (Q3 YTD FY22: £6.3m) following the cessation of capitalisation
of SPR shrimp development costs at the end of the prior year.
Adjusted EBITDA (excluding fair value movement from biological assets) was
£25.4m (Q3 YTD FY22: £20.0m) driven by higher revenues, increased asset
utilisation and ongoing cost control. As a result, the Group achieved an
Adjusted EBITDA margin (excluding fair value movement from biological assets)
of 19% (Q3 YTD FY22: 17%). Depreciation and amortisation decreased 3% from
the comparative period last year to £28.1m (Q3 YTD FY22: £29.0m), leaving
the operating loss in the period at £4.2m (Q3 YTD FY22: £6.1m).
There was a significant decrease in net finance costs for Q3 YTD to £2.4m (Q3
YTD FY22: £10.3m), primarily due to the portion of the movement in the fair
value of the derivative instrument which is ineffective for hedge accounting
purposes and forex movements. Ineffective movements in the fair value of the
derivative instruments were a gain of £3.7m (Q3 YTD FY22: £1.7m loss) and
there were net forex gains of £0.5m (Q3 YTD FY22: £2.6m loss). Interest
costs, including interest on right of use assets, were £1.2m higher than
prior year following the refinancing at the end of FY22. Together this led
to a Q3 YTD FY23 loss before tax of £6.6m significantly below the loss in the
previous year of £16.4m. There was a lower income tax charge in the period of
£1.4m (YTD Q3 FY22: £5.2m) due to lower profits in the territories with no
available loss reliefs, leaving loss after tax of £8.0m significantly below
the prior year (Q3 YTD FY22: loss after tax £21.6m).
Year to date, the Group reported a net operating cash inflow of £11.2m after
an increase in working capital of £5.3m mainly due to a reduction in payables
in the nutrition business which has had low sales in recent months. Net cash
outflow from investing activities was £11.3m, £8.0m of which was spent in
acquiring the minority interest in Benchmark Genetics Iceland. Capex was
£4.2m primarily in Genetics (£2.8m) and Health (£1.2m) and capitalised
R&D was £0.4m mostly incurred in Health, both of which were offset by
receipts of deferred consideration from earlier year disposals of divested
businesses of £1.3m. Our cash position at the end of the period was £32.9m
and liquidity of £45.1m.
Outlook
YTD Q3 FY23 the Group has delivered double digit revenue growth of 15% and 27%
increase in Adjusted EBITDA excluding FV movement from biological assets. This
demonstrates the momentum in our business and resilience of our diversified
business model to face cyclical fluctuations in our end markets.
Looking forward conditions in the salmon remain favourable while the global
shrimp markets are expected to remain unchanged for the rest of the year. We
anticipate a seasonal improvement in sales of our Health solutions and
continue to have good visibility of our Genetics revenues. There is continued
commercial focus in the business, and the Group is trading within market
expectations for the full year.
All figures in £000's Notes Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Revenue 4 34,267 36,272 133,129 115,519 158,277
Cost of sales (16,990) (16,799) (66,807) (56,524) (75,149)
Gross profit 17,277 19,473 66,322 58,995 83,128
Research and development costs (1,496) (1,426) (4,494) (4,663) (6,691)
Other operating costs (10,639) (11,464) (34,682) (31,371) (44,661)
Share of (loss)/profit of equity-accounted investees, net of tax (55) (10) 1 (538) (595)
Adjusted EBITDA² 5,087 6,573 27,147 22,423 31,181
Exceptional - restructuring, disposal and acquisition related items 5 (530) (469) (3,218) 439 16
EBITDA¹ 4,557 6,104 23,929 22,862 31,197
Depreciation and impairment (4,702) (5,206) (13,868) (15,258) (19,897)
Amortisation and impairment (4,318) (4,849) (14,230) (13,721) (19,161)
Operating profit/(loss) (4,463) (3,951) (4,169) (6,117) (7,861)
Finance cost 6 (2,981) (7,428) (13,207) (10,674) (20,057)
Finance income 6 2,746 141 10,762 409 4,741
Loss before taxation (4,698) (11,238) (6,614) (16,382) (23,177)
Tax on loss 7 76 (1,584) (1,407) (5,200) (7,274)
Loss for the period (4,622) (12,822) (8,021) (21,582) (30,451)
Loss for the period attributable to:
- Owners of the parent (5,153) (13,394) (9,294) (22,526) (32,087)
- Non-controlling interest 531 572 1,273 944 1,636
(4,622) (12,822) (8,021) (21,582) (30,451)
Earnings per share
Basic loss per share (pence) 8 (0.70) (1.90) (1.27) (3.24) (4.60)
Diluted loss per share (pence) 8 (0.70) (1.90) (1.27) (3.24) (4.60)
1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment
2 Adjusted EBITDA - EBITDA before exceptional items including acquisition
related items
All figures in £000's Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Loss for the period (4,622) (12,822) (8,021) (21,582) (30,451)
Other comprehensive income
Items that are or may be reclassified subsequently to profit or loss
Foreign exchange translation differences (11,153) 17,180 (35,166) 24,381 47,606
Cash flow hedges - changes in fair value 2,093 (2,368) 1,794 580 2,627
Cash flow hedges - reclassified to profit or loss (273) (19) (565) 159 2,546
Total comprehensive income for the period (13,955) 1,971 (41,958) 3,538 22,328
Total comprehensive income for the period attributable to:
- Owners of the parent (14,204) 1,381 (42,250) 2,217 20,326
- Non-controlling interest 249 590 292 1,321 2,002
(13,955) 1,971 (41,958) 3,538 22,328
The accompanying notes are an integral part of this consolidated financial
information.
30 June 2023 30 June 2022 30 September 2022
All figures in £000's Notes (unaudited) (unaudited) (audited)
Assets
Property, plant and equipment 71,880 81,478 81,900
Right-of-use assets 21,755 29,060 27,034
Intangible assets 205,312 235,175 245,264
Equity-accounted investees 3,028 3,086 3,113
Other investments 13 15 15
Biological and agricultural assets 21,688 20,927 20,878
Non-current assets 323,676 369,741 378,204
Inventories 26,244 27,228 29,813
Biological and agricultural assets 21,301 23,636 25,780
Trade and other receivables 47,858 51,105 56,377
Cash and cash equivalents 32,858 38,179 36,399
128,261 140,148 148,369
Assets held for sale 9 850 - -
Current assets 129,111 140,148 148,369
Total assets 452,787 509,889 526,573
Liabilities
Trade and other payables (32,034) (41,243) (44,324)
Loans and borrowings 10 (21,757) (14,226) (17,091)
Corporation tax liability (6,791) (7,408) (10,211)
Provisions (1,557) (543) (1,631)
Current liabilities (62,139) (63,420) (73,257)
Loans and borrowings 10 (77,960) (113,094) (93,045)
Other payables (4,908) (1,055) (8,996)
Deferred tax (22,755) (28,116) (27,990)
Non-current liabilities (105,623) (142,265) (130,031)
Total liabilities (167,762) (205,685) (203,288)
Net assets 285,025 304,204 323,285
Issued capital and reserves attributable to owners of the parent
Share capital 11 739 704 704
Additional paid-in share capital 11 37,428 420,824 420,824
Capital redemption reserve 5 5 5
Retained earnings 197,168 (175,866) (185,136)
Hedging reserve 526 (5,137) (703)
Foreign exchange reserve 43,520 54,469 77,705
Equity attributable to owners of the parent 279,386 294,999 313,399
Non-controlling interest 5,639 9,205 9,886
Total equity and reserves 285,025 304,204 323,285
The accompanying notes are an integral part of this consolidated financial
information.
Share Additional paid-in share capital* Other Hedging Retained Total attributable Non- Total
capital
reserves
reserve
earnings
to equity holders of
controlling
equity
parent
interest
£000 £000 £000 £000 £000 £000 £000 £000
As at 1 October 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
Comprehensive income/(loss) for the period
Profit/(loss) for the period - - - - (9,294) (9,294) 1,273 (8,021)
Other comprehensive income/(loss) - - (34,185) 1,229 - (32,956) (981) (33,937)
Total comprehensive income/(loss) for the period - - (34,185) 1,229 (9,294) (42,250) 292 (41,958)
Contributions by and distributions to owners
Share issue 35 12,985 - - - 13,020 - 13,020
Share issue costs recognised through equity - (2,146) - - - (2,146) - (2,146)
Cancellation of part of share premium account (note 11) - (394,235) - - 394,235 - - -
Share-based payment - - - - 833 833 - 833
Total contributions by and distributions to owners 35 (383,396) - - 395,068 11,707 - 11,707
Changes in ownership
Acquisition of NCI - - - - (3,470) (3,470) (4,539) (8,009)
Total changes in ownership interests - - - - (3,470) (3,470) (4,539) (8,009)
Total transactions with owners of the Company 35 (383,396) - - 391,598 8,237 (4,539) 3,698
As at 30 June 2023 (unaudited) 739 37,428 43,525 526 197,168 279,386 5,639 285,025
As at 1 October 2021 (audited) 670 400,682 30,470 (5,876) (154,231) 271,715 7,884 279,599
Comprehensive income/(loss)for the period
Profit/(loss) for the period - - - - (22,526) (22,526) 944 (21,582)
Other comprehensive income/(loss) - - 24,004 739 - 24,743 377 25,120
Total comprehensive income/(loss)for the period - - 24,004 739 (22,526) 2,217 1,321 3,538
Contributions by and distributions to owners
Share issue 34 20,704 - - - 20,738 - 20,738
Share issue costs recognised through equity - (562) - - - (562) - (562)
Share-based payment - - - - 891 891 - 891
Total contributions by and distributions to owners 34 20,142 - - 891 21,067 - 21,067
Changes in ownership
Total changes in ownership interests - - - - - - - -
Total transactions with owners of the Company 34 20,142 - - 891 21,067 - 21,067
As at 30 June 2022 (unaudited) 704 420,824 54,474 (5,137) (175,866) 294,999 9,205 304,204
As at 1 October 2021 (audited) 670 400,682 30,470 (5,876) (154,231) 271,715 7,884 279,599
Comprehensive income/(loss) for the period
Profit/(loss) for the period - - - - (32,087) (32,087) 1,636 (30,451)
Other comprehensive income/(loss) - - 47,240 5,173 - 52,413 366 52,779
Total comprehensive income/(loss) for the period - - 47,240 5,173 (32,087) 20,326 2,002 22,328
Contributions by and distributions to owners
Share issue 34 20,704 - - - 20,738 - 20,738
Share issue costs recognised through equity - (562) - - - (562) - (562)
Share-based payment - - - - 1,182 1,182 - 1,182
Total contributions by and distributions to owners 34 20,142 - - 1,182 21,358 - 21,358
Changes in ownership
Total changes in ownership interests - - - - - - - -
Total transactions with owners of the Company 34 20,142 - - 1,182 21,358 - 21,358
As at 30 September 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve
30 June 30 June 30 September 2022
2023
2022
Notes (unaudited) (unaudited) (audited)
Cash flows from operating activities
Loss for the period (8,021) (21,582) (30,451)
Adjustments for:
Depreciation and impairment of property, plant and equipment 6,363 6,324 8,602
Depreciation and impairment of right-of-use assets 7,505 8,934 11,295
Amortisation and impairment of intangible fixed assets 14,230 13,721 19,161
Loss on sale of property, plant and equipment (36) (43) (43)
Finance income (4,195) (238) (319)
Finance costs 7,173 7,913 18,437
Increase in fair value of contingent consideration receivable - (1,203) (1,203)
Share of (loss)/profit of equity-accounted investees, net of tax (1) 538 595
Foreign exchange (losses)/gains (2,443) 5,607 (3,985)
Share-based payment expense 833 891 1,182
Other adjustments for non-cash items - - (276)
Tax charge 1,407 5,200 7,274
Decrease/(increase) in trade and other receivables 3,772 (4,456) (8,511)
Decrease/(increase) in inventories 2,249 (7,314) (5,406)
Increase in biological and agricultural assets (403) (4,144) (6,099)
(Decrease)/increase in trade and other payables (10,862) (6,228) 6,946
(Decrease)/increase in provisions (20) (21) 1,058
17,551 3,899 18,257
Income taxes paid (6,335) (6,100) (7,447)
Net cash flows generated from operating activities 11,216 (2,201) 10,810
Investing activities
Acquisition of minority interests in subsidiaries, net of cash acquired 14 (8,009) - -
Acquisition of subsidiaries 14 (48) - -
Purchase of investments (359) (108) (378)
Receipts from disposal of investments 14 1,250 919 1,544
Purchases of property, plant and equipment (4,171) (7,169) (10,808)
Purchase of intangibles (120) (1,757) (205)
Capitalised research and development costs (380) - (1,708)
Proceeds from sale of fixed assets 99 194 220
Interest received 469 34 119
Net cash flows used in investing activities (11,269) (7,887) (11,216)
Financing activities
Proceeds of share issues 13,020 20,782 20,737
Share-issue costs recognised through equity (2,146) (607) (562)
Proceeds from bank or other borrowings 21,984 - 67,939
Repayment of bank or other borrowings (17,527) (1,333) (74,874)
Capitalised borrowing costs (1,159) - -
Interest and finance charges paid (6,736) (5,381) (9,629)
Repayments of lease liabilities (7,349) (6,928) (10,533)
Net cash inflow/(outflow) from financing activities 87 6,533 (6,922)
Net increase/(decrease) in cash and cash equivalents 34 (3,555) (7,328)
Cash and cash equivalents at beginning of period 36,399 39,460 39,460
Effect of movements in exchange rate (3,575) 2,274 4,267
Cash and cash equivalents at end of period 32,858 38,179 36,399
1. Basis of preparation
Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled
in the United Kingdom. These consolidated quarterly financial statements as at
and for the nine months ended 30 June 2023 comprises those of the Company and
its subsidiaries (together referred to as the 'Group').
These consolidated quarterly financial statements do not comprise statutory
accounts within the meaning of section 434 of the Companies Act 2006 and are
unaudited. These financial statements do not include all the information
required for a complete set of IFRS financial statements. However, selected
explanatory notes are included to explain events and transactions that are
significant to an understanding of the changes in the Group's financial
position and performance since the last annual financial statements. The
Group's last annual statutory financial statements as at and for the year
ended 30 September 2022 were prepared in accordance with UK adopted
international accounting standards in conformity with the requirements of the
Companies Act 2006 as it applies to companies reporting under those standards
("Adopted IFRS") and are available from the Company's website at
www.benchmarkplc.com (http://www.benchmarkplc.com) .
The prior year comparatives are derived from audited financial information for
Benchmark Holdings PLC Group as set out in the Annual Report and Accounts for
the year ended 30 September 2022 and the unaudited financial information in
the Quarterly Financial Report for the nine months ended 30 June 2022. The
comparative figures for the financial year ended 30 September 2022 are not the
Company's statutory accounts for that financial year. Those accounts were
approved by the Directors on 30 November 2022 and have been delivered to the
Registrar of Companies. The audit report received on those accounts was (i)
unqualified and (ii) did not include a reference to any matters to which the
external auditor drew attention by way of emphasis without qualifying their
report, and (iii) did not contain a statement under section 498(2) or (3) of
the Companies Act 2006.
Statement of Compliance
These consolidated quarterly financial statements have been prepared in
accordance with UK and EU adopted IAS 34 'Interim Financial Reporting'. These
financial statements do not include all of the information required for the
full annual financial statements and should be read in conjunction with the
Group's last annual consolidated financial statements as at and for the year
ended 30 September 2022. These consolidated quarterly financial statements
were approved by the Board of Directors on 24 August 2023.
Going concern
The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.
As at 30 June 2023 the Group had net assets of £285.0m (30 September 2022:
£323.3m), including cash of £32.9m (30 September 2022: £36.4m) as set out
in the consolidated balance sheet. The Group made a loss for the nine months
of £8.0m (year ended 30 September 2022: loss £30.5m).
As noted in the Management Report, the business has continued to perform
steadily in the first nine months and has shown resilience to some tough
market conditions in recent months, with results in line with expectations.
The Directors have reviewed forecasts and cash flow projections for a period
of at least 12 months including downside sensitivity assumptions in relation
to trading performance across the Group to assess the impact on the Group's
trading and cash flow forecasts and on the forecast compliance with the
covenants included within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan® Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduced treatment prices. Key downside
sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth both in Chile
and to land-based farms in Genetics, along with sensitivities on sales price
increases and demand for artemia feeds in certain territories. Mitigating
measures within the control of management have been identified should they be
required in response to these sensitivities, including reductions in areas of
discretionary spend, tight control over new hires, and deferral of capital
projects.
The refinancing exercise which commenced in FY22 was completed in Q1 FY23, so
that adequate finance facilities are in place, and with financial instruments
in place to fix interest rates and opportunities available to mitigate
globally high inflation rates, the Group continues to show resilience against
current global economic pressures. The Directors are therefore confident
that even under all of the above sensitivity analysis, the Group has
sufficient liquidity and resources throughout the period u der review whilst
still maintaining adequate headroom against the borrowing covenants and remain
confident that the Group has adequate resources to continue to meet its
liabilities as and when they fall due within the period of 12 months from the
date of approval of these financial statements. Based on their assessment, the
Directors believe it remains appropriate to prepare the financial statements
on a going concern basis.
2. Accounting policies
The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2022.
Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.
Alternative performance measures ('APMs')
The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by EU-adopted IFRS.
These APMs may not be directly comparable with other companies' APMs, and the
Directors do not intend these as a substitute for, or superior to, IFRS
measures.
Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 12).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using the
prior year's foreign exchange rates.
Use of estimates and judgements
The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.
In preparing these quarterly financial statements the significant judgements
made by management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those applied to the
consolidated financial statements for the year ended 30 September 2022.
3. Segment information
Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.
The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:
· Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.
· Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.
· Health - the segment provides health products and services to the
global aquaculture market.
3. Segment information (continued)
In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.
Measurement of operating segment profit or loss
Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities. This policy
was applied consistently throughout the current and prior period.
Segmental Revenue
All figures in £000's Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Genetics 14,426 13,091 48,907 39,694 58,008
Advanced Nutrition 16,067 19,381 61,391 61,414 80,286
Health 3,795 3,840 22,872 14,533 20,135
Corporate 1,426 1,406 4,299 4,218 5,120
Inter-segment sales (1,447) (1,446) (4,340) (4,340) (5,272)
Total 34,267 36,272 133,129 115,519 158,277
Segmental Adjusted EBITDA
All figures in £000's Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Genetics 3,356 4,816 9,339 10,507 15,980
Advanced Nutrition 3,420 2,837 14,886 14,311 19,017
Health (1,022) (610) 5,628 (517) 108
Corporate (667) (470) (2,706) (1,878) (3,924)
Total 5,087 6,573 27,147 22,423 31,181
Reconciliations of segmental information to IFRS measures
Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
taxation
All figures in £000's Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Total reportable segment Adjusted EBITDA 5,754 7,043 29,853 24,301 35,105
Corporate Adjusted EBITDA (667) (470) (2,706) (1,878) (3,924)
Adjusted EBITDA 5,087 6,573 27,147 22,423 31,181
Exceptional - restructuring, disposal and acquisition related items (530) (469) (3,218) 439 16
Depreciation and impairment (4,702) (5,206) (13,868) (15,258) (19,897)
Amortisation and impairment (4,318) (4,849) (14,230) (13,721) (19,161)
Net finance costs (235) (7,287) (2,445) (10,265) (15,316)
Loss before taxation (4,698) (11,238) (6,614) (16,382) (23,177)
4. Revenue
The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2022. The Group's revenue is derived from
contracts with customers.
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).
Sale of goods and provision of services
3 months ended 30 June 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 13,523 16,049 2,259 - - 31,831
Provision of services 900 - 1,536 - - 2,436
Inter-segment sales 3 18 - 1,426 (1,447) -
14,426 16,067 3,795 1,426 (1,447) 34,267
3 months ended 30 June 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 12,148 19,346 3,598 - - 35,092
Provision of services 938 - 242 - - 1,180
Inter-segment sales 5 35 - 1,406 (1,446) -
13,091 19,381 3,840 1,406 (1,446) 36,272
9 months ended 30 June 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 45,727 61,356 15,823 - - 122,906
Provision of services 3,174 - 7,049 - - 10,223
Inter-segment sales 6 35 - 4,299 (4,340) -
48,907 61,391 22,872 4,299 (4,340) 133,129
9 months ended 30 June 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 36,529 61,339 9,443 - - 107,311
Provision of services 3,118 - 5,090 - - 8,208
Inter-segment sales 47 75 - 4,218 (4,340) -
39,694 61,414 14,533 4,218 (4,340) 115,519
4. Revenue (continued)
Sale of goods and provision of services (continued)
12 months ended 30 September 2022 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 53,978 80,191 13,528 - - 147,697
Provision of services 3,973 - 6,607 - - 10,580
Inter-segment sales 57 95 - 5,120 (5,272) -
58,008 80,286 20,135 5,120 (5,272) 158,277
Primary geographical markets
3 months ended 30 June 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 7,190 349 3,155 - - 10,694
India - 671 - - - 671
Turkey 54 1,208 - - - 1,262
Greece - 1,698 - - - 1,698
Faroe Islands 1,668 - 116 - - 1,784
Ecuador 9 1,936 - - - 1,945
United Kingdom 783 27 93 - - 903
Chile 332 1 291 - - 624
Vietnam - 2,445 - - - 2,445
Rest of Europe 1,546 767 - - - 2,313
Rest of World 2,841 6,947 140 - - 9,928
Inter-segment sales 3 18 - 1,426 (1,447) -
14,426 16,067 3,795 1,426 (1,447) 34,267
3 months ended 30 June 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 7,721 328 2,411 - - 10,460
India 181 3,208 - - - 3,389
Turkey - 1,173 - - - 1,173
Greece 2 1,795 - - - 1,797
Faroe Islands 1,325 1 101 - - 1,427
Ecuador 18 1,575 - - - 1,593
United Kingdom 363 39 48 - - 450
Chile 429 2 96 - - 527
Vietnam - 4,022 - - - 4,022
Rest of Europe 1,591 631 - - - 2,222
Rest of World 1,456 6,572 1,184 - - 9,212
Inter-segment sales 5 35 - 1,406 (1,446) -
13,091 19,381 3,840 1,406 (1,446) 36,272
4. Revenue (continued)
Primary geographical markets (continued)
9 months ended 30 June 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 30,251 691 17,607 - - 48,549
India - 7,696 - - - 7,696
Turkey 60 5,940 - - - 6,000
Greece - 5,969 - - - 5,969
Faroe Islands 4,987 - 464 - - 5,451
Ecuador 38 5,508 - - - 5,546
United Kingdom 2,334 54 135 - - 2,523
Chile 1,465 12 633 - - 2,110
Vietnam - 7,475 - - - 7,475
Rest of Europe 5,288 4,105 - - - 9,393
Rest of World 4,478 23,906 4,033 - - 32,417
Inter-segment sales 6 35 - 4,299 (4,340) -
48,907 61,391 22,872 4,299 (4,340) 133,129
9 months ended 30 June 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 23,515 651 11,367 - - 35,533
India 581 10,927 - - - 11,508
Turkey - 5,105 - - - 5,105
Greece 2 5,266 - - - 5,268
Faroe Islands 3,926 7 378 - - 4,311
Ecuador 18 3,866 - - - 3,884
United Kingdom 3,219 67 166 - - 3,452
Chile 769 7 649 - - 1,425
Vietnam - 10,031 - - - 10,031
Rest of Europe 4,952 3,212 - - - 8,164
Rest of World 2,665 22,200 1,973 - - 26,838
Inter-segment sales 47 75 - 4,218 (4,340) -
39,694 61,414 14,533 4,218 (4,340) 115,519
4. Revenue (continued)
Primary geographical markets (continued)
12 months ended 30 September 2022 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 34,666 965 15,571 - - 51,202
India 619 12,001 - - - 12,620
Turkey - 6,419 - - - 6,419
Greece 2 6,197 - - - 6,199
Faroe Islands 5,465 9 587 - - 6,061
Ecuador 18 6,472 - - - 6,490
United Kingdom 4,318 93 199 - - 4,610
Chile 1,006 15 871 - - 1,892
Vietnam - 10,512 - - - 10,512
Rest of Europe 7,110 4,056 - - - 11,166
Rest of World 4,747 33,452 2,907 - - 41,106
Inter-segment sales 57 95 (0) 5,120 (5,272) (0)
58,008 80,286 20,135 5,120 (5,272) 158,277
5. Exceptional - restructuring, disposal, and acquisition related
items
Items that are material because of their size or nature, non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.
All figures in £000's Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Acquisition related items 579 - 579 - -
Exceptional restructuring costs 153 508 2,826 606 1,229
(Income)/cost in relation to disposals (201) (39) (186) (1,045) (1,245)
Total exceptional items 530 469 3,218 (439) (16)
Acquisition related items comprise fees incurred in the period in connection
with an aborted
acquisition.
Exceptional restructuring costs include £43,000 for the quarter (Q3 2022:
£331,000) and £2,580,000 YTD (Q3 YTD 2022: £371,000) of legal and
professional costs in relation to preparing for listing the Group on the Oslo
stock exchange, and £110,000 for the quarter (Q3 2022: £177,000) and
£246,000 YTD (Q3 YTD 2022: £235,000) relating to other restructuring
costs.
(Income)/costs in relation to disposals in the quarter and YTD relate to a
credit of £235,000 (Q3 2022: £294,000 credit; Q3 YTD 2022: £1,202,000) due
to higher than anticipated deferred consideration received from subsidiary
company disposals made in 2020 offset by £34,000 (Q3 2022: £255,000) in Q3
and £49,000 in the year to date (Q3 YTD 2022: £157,000) of other disposal
costs.
6. Net finance costs
All figures in £000's Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Interest received on bank deposits 155 9 472 238 319
Foreign exchange gains on financing activities 158 - 158 - 4,422
Foreign exchange gains on operating activities 1,363 114 6,409 171 -
Cash flow hedges - reclassified from OCI 273 19 565 - -
Cash flow hedges - ineffective portion of changes in fair value 798 - 3,158 - -
Finance income 2,746 141 10,762 409 4,741
Leases (interest portion) (390) (24) (1,262) (717) (1,744)
Cash flow hedges - reclassified from OCI - - - (159) (2,546)
Cash flow hedges - ineffective portion of changes in fair value - (2,318) - (1,562) (4,475)
Foreign exchange gains on financing activities - (1,542) - (1,984) -
Foreign exchange losses on operating activities (175) (1,683) (6,034) (777) (1,620)
Interest expense on financial liabilities measured at amortised cost (2,416) (1,863) (5,911) (5,475) (9,672)
Finance costs (2,981) (7,428) (13,207) (10,674) (20,057)
Net finance costs recognised in profit or loss (235) (7,287) (2,445) (10,265) (15,316)
7. Taxation
All figures in £000's Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Analysis of charge in period
Current tax:
Current income tax expense on profits for the period 823 2,596 3,658 7,603 11,727
Adjustment in respect of prior periods - - - - (39)
Total current tax charge 823 2,596 3,658 7,603 11,688
Deferred tax:
Origination and reversal of temporary differences (899) (1,012) (2,251) (2,403) (4,414)
Deferred tax movements in respect of prior periods - - - - -
Total deferred tax credit (899) (1,012) (2,251) (2,403) (4,414)
- -
Total tax (credit)/charge (76) 1,584 1,407 5,200 7,274
8. Loss per share
Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.
Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Loss attributable to equity holders of the parent (£000) (5,153) (13,394) (9,294) (22,526) (32,087)
Weighted average number of shares in issue (thousands) 739,300 703,961 729,437 696,303 698,233
Basic loss per share (pence) (0.70) (1.90) (1.27) (3.24) (4.60)
Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.
Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.
A total of 5,988,043 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2022: 6,240,304 and 30 June 2022: 5,066,469). These potential ordinary shares
could dilute earnings/loss per share in the future.
9. Assets held for sale
This property was transferred to assets held for sales at £850,000, which is
the book value and market value.
Assets held for sale Transferred to held for sale Fair value adjustment Total assets transferred
All figures in £000's
Property, plant and equipment 850 - 850
Total Assets held for sale 850 - 850
10. Loans and borrowings
YTD Q3 2023 YTD Q3 2022 FY 2022
All figures in £000's (unaudited) (unaudited) (audited)
Non-Current
2025 750m NOK Loan notes 53,382 - 61,054
2023 850m NOK Loan notes - 78,172 -
Bank borrowings 15,746 17,771 17,226
Lease liabilities 8,832 17,151 14,765
77,960 113,094 93,045
Current
Bank borrowings 9,439 1,583 5,569
Lease liabilities 12,318 12,643 11,522
21,757 14,226 17,091
Total loans and borrowings 99,717 127,320 110,136
On 27 September 2022, the Group successfully issued a new unsecured floating
rate listed green bond of NOK 750m. The bond which matures in September 2025,
has a coupon of three-month NIBOR + 6.50% p.a. with quarterly interest
payments, and is to be listed on the Oslo Stock Exchange. The proceeds were
used to repay its existing NOK 850m floating rate listed bond, originally
raised in June 2019.
On 21 November 2022, the Group refinanced its USD15m RCF, which was provided
by DNB Bank ASA (50%) and HSBC UK Bank PLC (50%), with a secured GBP20m RCF
provided by DNB Bank ASA, maturing on 27 June 2025. The margin on this
facility is a minimum of 2.75% and a maximum of 3.25%, dependent upon the
leverage of the Group above the relevant risk-free reference or IBOR rates
depending on which currency is drawn.
On 15 February 2023, the Group drew down €9,000,000 on the GBP20,000 RCF. On
16 June 2023 this was repaid by a further draw down from the RCF of
£7,750,000, leaving £12,250,000 undrawn as at 30 June 2023.
Additionally on 1 November 2022, the Group's Nordea Bank term loan of NOK
165.6m, which had a term loan of five years ending in November 2023 and
interest rate of 2.5% above three month NIBOR, was refinanced together with an
existing undrawn overdraft facility into a new loan facility of NOK 179.5m
with a new maturity date in a further five years no later than 15 January
2028. Other terms of this facility remain the same.
11. Share capital and additional paid-in share capital
Number Share Capital Additional paid-in
share capital
Allotted, called up and fully paid £000 £000
Ordinary shares of 0.1 pence each
Balance at 30 September 2022 703,960,798 704 420,824
Shares issued through placing and open offer 35,189,350 35 10,839
Cancellation of part of the share premium account (394,235)
Exercise of share options 127,321 - -
Balance at 30 June 2023 739,277,469 739 37,428
On 15 December 2022, the Company issued 35,189,350 new ordinary shares of 0.1
pence each by way of a placing and subscriptions at an issue price of 37.0
pence per share. Gross proceeds of £13.0m were received for the placing and
subscription shares. Non-recurring costs of £2.1m were in relation to the
share issue and this has been charged to the share premium account (presented
within additional paid-in share capital).
The share premium account is used to record the aggregate amount of value of
the premiums paid when the Company's shares are issued/redeemed at a premium.
On 20 March 2023, part of the Company's share premium account was cancelled
following the confirmation of the capital reduction by the High Court of
England and Wales on 14 March 2023 and the subsequent registration of the
court order with the Registrar of Companies. The capital reduction created
additional distributable reserves to the value of £394,235,072.
12. Alternative performance measures and other metrics
Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.
Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
and is shown on the Income Statement.
Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.
Adjusted Operating Profit is operating loss before exceptional items and
amortisation and impairment of intangible assets excluding development costs
as reconciled below.
Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items as
reconciled below. These measures are not defined performance measures in IFRS.
The Group's definition of these measures may not be comparable with similarly
titled performance measures and disclosures by other entities.
12. Alternative performance measures and other metrics (continued)
Reconciliation of Adjusted Operating Profit to Operating Loss
All figures in £000's Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Revenue 34,267 36,272 133,129 115,519 158,277
Cost of sales (16,990) (16,799) (66,807) (56,524) (75,149)
Gross profit 17,277 19,473 66,322 58,995 83,128
Research and development costs (1,496) (1,426) (4,494) (4,663) (6,691)
Other operating costs (10,639) (11,464) (34,682) (31,371) (44,661)
Depreciation and impairment (4,702) (5,206) (13,868) (15,258) (19,897)
Amortisation of capitalised development costs (606) (605) (1,833) (1,550) (2,165)
Share of loss of equity accounted investees net of tax (55) (10) 1 (538) (595)
Adjusted operating (loss)/profit (221) 762 11,446 5,615 9,119
Exceptional - restructuring, disposal and acquisition related items (530) (469) (3,218) 439 16
Amortisation and impairment of intangible assets excluding development costs (3,712) (4,244) (12,397) (12,171) (16,996)
Operating loss (4,463) (3,951) (4,169) (6,117) (7,861)
Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax
All figures in £000's Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Loss before taxation (4,698) (11,238) (6,614) (16,382) (23,177)
Exceptional - restructuring, disposal and acquisition related items 530 469 3,218 (439) (16)
Amortisation and impairment of intangible assets excluding development costs 3,712 4,244 12,397 12,171 16,996
Adjusted (loss)/profit before tax (456) (6,525) 9,001 (4,650) (6,197)
Other Metrics
All figures in £000's Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Total R&D Investment
Research and development costs 1,496 1,426 4,494 4,663 6,691
Internal capitalised development costs 183 192 380 1,596 1,708
Total R&D investment 1,679 1,618 4,874 6,259 8,399
All figures in £000's Q3 2023 Q3 2022 YTD Q3 2023 YTD Q3 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Adjusted EBITDA excluding fair value movement in biological assets
Adjusted EBITDA 5,087 6,573 27,147 22,423 31,181
Exclude fair value movement (1,457) (1,437) (1,704) (2,442) (1,595)
Adjusted EBITDA excluding fair value movement in biological assets 3,630 5,136 25,443 19,981 29,586
12. Alternative performance measures and other metrics (continued)
Liquidity
A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.
30 June 2023
All figures in £000's (unaudited)
Cash and cash equivalents 32,858
Undrawn bank facility 12,250
45,108
The undrawn bank facility relates to the RCF facility. At 30 June 2023,
£7.8m of the RCF was drawn (30 September 2022: £4m and 31 March 2022:
£nil), leaving £12.3m undrawn (30 September 2022: £9.4m and 31 March 2022:
£nil).
13. Net debt
Net debt is cash and cash equivalents less loans and borrowings.
30 June 2023 30 June 2022 30 September 2022
All figures in £000's (unaudited) (unaudited) (audited)
Cash and cash equivalents 32,858 38,179 36,399
Loans and borrowings (excluding lease liabilities) - current (9,439) (1,583) (5,569)
Loans and borrowings (excluding lease liabilities) - non-current (69,128) (95,943) (78,280)
Net debt excluding lease liabilities (45,709) (59,347) (47,450)
Lease liabilities - current (12,318) (12,643) (11,522)
Lease liabilities - non-current (8,832) (17,151) (14,765)
Net debt (66,859) (89,141) (73,737)
14. Business combinations and transactions in subsidiary companies
In June, the Group acquired 66% of the issued share capital of Baggfossen
Mikrokraft AS to bring the total owned to 100% for consideration of £48,000.
The goodwill has been impaired in the period. The following table shows the
consideration paid and the fair value of the assets acquired.
Total
£000
Consideration
Cost of investment 48
Satisfied by:
Cash 48
Total consideration 48
Fair value of assets acquired
Fixed assets 307
Accounts Receivable (13)
Other receivables 1
Financial instrument - interest rate swap 10
Accounts payable (1)
Other current liabilities - advance from customers (3)
Bank loan (235)
Advance from Salten Stamfisk (10)
Advance from BG Salten (12)
Total identifiable net assets 44
Goodwill 4
On 15 February 2023, the Group purchased the minority interest's shareholding
of 14,981,272 shares in Benchmark Genetics Iceland HF for €9,000,000.
Following this acquisition, Benchmark Genetics Limited, a subsidiary of
Benchmark Holdings PLC, now owns 100% of the share capital of Benchmark
Genetics Iceland HF.
On 6 February 2023, the Group exercised the put/call option in place to
purchase the final 20% of Benchmark Genetics USA Inc for 1 NOK.
On 11 May 2023, the Group received £1,250,000 as the final part of the
deferred consideration for Improve International Limited and its subsidiaries
which was sold in June 2020.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END QRTEAPPDALSDEFA